ReviewDiscover nano2026
Plant-derived extracellular vesicles as a promising therapeutic and drug delivery strategy for tumor oxidative stress and inflammation.
Review in Discover nano, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Oxidative stress and chronic inflammation are key factors in tumor progression. Existing antioxidant and anti-inflammatory treatment methods are limited due to their specificity, bioavailability and impact on non-target sites. Plant-derived extracellular vesicles (PDEVs), as an innovative category of natural nanocarriers, effectively integrate therapeutic and delivery capabilities. They provide direct antioxidant and anti-inflammatory benefits by transporting bioactive phytochemicals and influencing key pathways. In addition, its inherent lipid bilayer structure promotes the effective encapsulation of therapeutic agents. Compared with synthetic systems, it has significant advantages in terms of biocompatibility, low immunogenicity and oral administration potential. However, the clinical application of PDEVs is hindered by challenges such as standardized isolation, batch-to-batch variability, unclear in vivo pharmacokinetics, and scalability. This review provides a critical synthesis of the current knowledge on PDEV biology, mechanisms of action, and engineering strategies, while offering a realistic analysis of translational prospects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.